Overview of the Offering
Disc Medicine, Inc. (NASDAQ: IRON), a biopharmaceutical company focused on innovative treatments for significant hematologic disorders, recently announced its pricing for a substantial public offering. The company is raising $250 million through this upsized offering, which includes common stock and pre-funded warrants. This initiative illustrates Disc's commitment to advancing its clinical programs aimed at treating severe blood-related conditions.
Details of the Offering
The offering consists of 2,619,049 shares of common stock, along with pre-funded warrants for an additional 59,523 shares of common stock. Notably, the common stock is priced at $84.00 per share, while the pre-funded warrants are available at $83.9999 each. The total gross proceeds from this offering are anticipated to be approximately $225 million for Disc, excluding discounts and expenses. Additionally, the Selling Stockholder plans to sell 297,619 shares, contributing another $25 million to the overall proceeds.
Use of Proceeds
Disc Medicine's strategy for utilizing the funds focuses on key growth areas. The majority of the net proceeds will be directed towards the commercialization efforts of bitopertin, a novel therapeutic candidate designed for specific hematologic conditions such as erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). Furthermore, funds will be allocated to support ongoing research and clinical development of current and future product candidates, along with maintaining working capital for day-to-day operations.
Underwriters and Management Team
The offering is supported by a robust team of financial experts. Jefferies, Leerink Partners, Morgan Stanley, and Cantor are the primary managers overseeing the underwriting process. In addition, Wedbush PacGrow and H.C. Wainwright & Co. have been appointed as co-managers, further enhancing the expertise involved in this pivotal offering.
Registration and Compliance
This public offering follows the guidelines set by the Securities and Exchange Commission and utilizes an automatic shelf registration statement filed on Form S-3. The offering is expected to close shortly, contingent upon the usual closing conditions, emphasizing the company's focus on compliance and regulatory integrity.
About Disc Medicine
Disc Medicine is dedicated to revolutionizing the treatment landscape for patients impacted by serious hematologic diseases. The company's innovative approach involves developing therapeutic candidates targeting core processes of red blood cell biology, particularly in areas concerning heme biosynthesis and iron regulation. This vision aligns with the growing need for advanced treatment options in hematology.
Company Contacts
For media inquiries, Peg Rusconi from Deerfield Group can be contacted via email at peg.rusconi@deerfieldgroup.com. For investor relations, Christina Tartaglia of Precision AQ is available at christina.tartaglia@precisionaq.com, providing valuable insights into the company's financial and strategic initiatives.
Frequently Asked Questions
What is the main goal of Disc Medicine's recent offering?
The primary aim is to raise funds for the commercialization of bitopertin for EPP and XLP, along with supporting research and development efforts.
Who are the underwriters for this offering?
The offering is managed by Jefferies, Leerink Partners, Morgan Stanley, and Cantor, with additional support from Wedbush PacGrow and H.C. Wainwright & Co.
How much total funding is Disc Medicine seeking?
Disc Medicine is seeking a total of $250 million from the public offering, consisting of both common stock and pre-funded warrants.
What therapeutic areas does Disc Medicine focus on?
Disc Medicine specializes in treatments for serious hematologic diseases, particularly addressing issues related to red blood cell biology.
Who can be contacted for further information about the offering?
For inquiries related to media, Peg Rusconi at Deerfield Group and Christina Tartaglia at Precision AQ are the primary contacts available.
